In the essential realm of healthcare, the pharmaceutical industry stands as a beacon of progress, vital for global well-being and economic prosperity. Pharmaceutical companies are closely inspected to guarantee the manufacturing of high-quality medications since they operate at the intersection of innovation and responsibility.
Governments, realizing how vital health is, keep a close eye on pharmaceutical activities to ensure that standards are maintained. Technology has made it possible for businesses like Emcure Pharmaceuticals to investigate a variety of drugs. Emcure is a prominent multinational company that specializes in producing tablets, capsules, and injectables. The company is dedicated to improving healthcare by using innovative approaches and searching for novel medications. Emcure Pharmaceuticals Limited is ranked as the 11th largest company in the Indian Pharmaceutical Market as per AWACS MAT Feb’24 data.
In this article, we will delve into the successful journey of Emcure Pharmaceuticals’ founder, business model, funding, competitors, IPO, and more.
Emcure Pharmaceuticals – Company Highlights
| STARTUP NAME | EMCURE PHARMACEUTICALS |
|---|---|
| Headquarters | Pune, Maharashtra, India |
| Sector | Pharmaceuticals |
| Founders | Satish Ramlal Mehta |
| Founded | 1981 |
| Revenue | INR 6,658 crore (FY24) |
| Website | emcure.com |
Emcure Pharmaceuticals – About
Emcure Pharmaceuticals – Subsidiaries
Emcure Pharmaceuticals – Industry
Emcure Pharmaceuticals – Founders and Team
Emcure Pharmaceuticals – Startup Story
Emcure Pharmaceuticals – Mission and Vision
Emcure Pharmaceuticals – Name, Tagline, and Logo
Emcure Pharmaceuticals – Business Model
Emcure Pharmaceuticals – Revenue Model
Emcure Pharmaceuticals – Challenges Faced
Emcure Pharmaceuticals – Funding and Investors
Emcure Pharmaceuticals – Growth
Emcure Pharmaceuticals – IPO
Emcure Pharmaceuticals – Marketing and Campaigns
Emcure Pharmaceuticals – Awards and Achievements
Emcure Pharmaceuticals – Competitors
Emcure Pharmaceuticals – Future Plans
Emcure Pharmaceuticals – About
Established in 1981, Emcure Pharmaceuticals has become a prominent participant in the Indian pharmaceutical industry, acknowledged worldwide for its wide array of offerings. Emcure, which is well-established in more than 70 countries, focuses on important therapeutic domains like HIV, gynecology, cardiology, cancer, respiratory, and central nervous system.
Six biologics have been launched by the business, in the domestic and Rest of the World (RoW) markets. During the COVID-19 pandemic, Emcure Pharma demonstrated its agility by founding Gennova, a subsidiary that spearheaded the creation of India’s first-ever indigenous mRNA vaccine. This demonstrates Emcure’s dedication to innovation and meeting pressing healthcare needs around the world. The turnover of the company for FY24 is INR 6658 crore.
Emcure Pharmaceuticals – Subsidiaries
Below is the list of Pharmaceuticals:
- Gennova Biopharmaceuticals Ltd.
- Zuventus Healthcare Ltd
- Emcure Nigeria Limited
- Emcure Pharmaceuticals Mena FZ-LLC
- Emcure Pharmaceuticals South Africa (Pty) Limited
- Emcure Brasil Farmaceutica Ltda
- Heritage Pharma Holdings Inc. d/b/a Avet Pharmaceuticals Holdings Inc.
- Emcure Pharma UK Ltd
- Emcure Pharma Peru S.A.C
- Emcure Pharma Mexico S.A. DE C.V
- Marcan Pharmaceuticals Inc
- Emcure Pharmaceuticals Pty Ltd
Emcure Pharmaceuticals – Industry
According to a Statista analysis, the pharmaceuticals market is expected to increase at a compound annual growth rate (CAGR) of 6.33% from 2024 to 2028. By 2028, the market volume is predicted to reach US $15.93 billion based on this trajectory.
With a predicted volume of US $2.02 billion in 2024, Oncology Drugs continues to be the leading market sector in this dynamic landscape. The strong revenue growth is indicative of the pharmaceutical industry’s overall resiliency and evolution in meeting a range of healthcare demands, as well as the growing emphasis on oncology therapies.
Emcure Pharmaceuticals – Founders and Team
The company was founded by Satish Ramanlal Mehta in 1981.
Satish Ramanlal Mehta
Satish Ranamnlal Mehta is the founder of Emcure Pharmaceuticals and also serves as the CEO and Managing Director of the company. He is a postgraduate in Chemistry from Pune University and has a diploma in management from the IIM, Ahmedabad.
Led by the visionary leadership of Satish Mehta, Emcure Pharmaceuticals has achieved esteemed recognition as a global pharmaceutical entity, operating in over 70 countries. The Emcure Pharmaceuticals subsidiaries are spread throughout important regions, such as the UK, Canada, Singapore, Brazil, and others, enhancing Emcure Pharmaceuticals’ prominence and power in the world pharmaceutical industry.
He has also served as a member of the Committee to recommend / frame Rules under the Indian Institutes of Management Act, 2017 – Ministry of HRD (Government of India), Economic & Commercial Consultative Group (ECCG) – NITI Aayog (Government of India), and India-China Bilateral Council – NITI Aayog (Government of India).
In 2016, Satish Mehta was ranked on the Forbes Rich List as the 82nd richest Indian with a net worth of $1.6 billion in 2018.
Namita Thapar
Namita Thapar is the Executive Director of Emcure Pharmaceuticals, and her career history is marked by excellence. Beginning her career as a Chartered Accountant with the Institute of Chartered Accountants of India, she honed her financial acumen. Adding to her credentials, Namita pursued an MBA at Duke University – The Fuqua School of Business.
Namita started her career at Abbott as a Senior Manager. Later, she became the Chief Financial Officer (CFO) of Emcure Pharmaceuticals, where her duties eventually expanded to include overseeing the company’s India division, which is its largest business unit. She also holds the position of Young Entrepreneurs Academy, Inc.’s India Head.
Namita Thapar is also an avid investor, and her support for Indian startups can be seen on the show Shark Tank India, where she has served as a prominent shark.
Sarika Anand
Sunil Mehta
Pharmaceuticals’Sunil Mehta is the Executive Director, at Emcure Pharmaceuticals. He is a graduate of Commerce from Pune University and a postgraduate in Business Administration from the Institute of Management Development and Research, Pune.
Sunil also serves on the board of Gennova Biopharmaceuticals Ltd., a prominent Emcure Pharmaceuticals subsidiary.
The company has over 10,000 employees.
Emcure Pharmaceuticals – Startup Story
In Pune, Maharashtra, India, Emcure Pharmaceuticals was founded by Mr. Satish Mehta, a visionary leader. Satish Mehta founded the company with his entrepreneurial energy and his knowledge of pharmaceutical science. His motivation came from a good goal: to enable patients in India and around the world to buy and obtain necessary medications.
After returning to Pune with a postgraduate credential from IIM-A, Satish immersed himself in his father’s pharmaceutical company to obtain knowledge of the nuances of the pharma sector, which marked a crucial turning point in his entrepreneurial journey. Driven by a vision for innovation and the desire to make a distinct mark, he secured a bank loan and embarked on the entrepreneurial journey that led to the inception of Emcure Pharmaceuticals.
Emcure Pharmaceuticals – Mission and Vision
The mission of the company is ” To constantly innovate and deliver affordable & high-quality healthcare solutions to people.”
The company vision on the website states, “To provide quality healthcare solutions globally by leveraging our scientific strengths.”
Emcure Pharmaceuticals – Name, Tagline, and Logo
The company goes by the tagline, “Cure and beyond.”.
Emcure Pharmaceuticals – Business Model
Emcure Pharmaceuticals has strategically crafted a focused go-to-market business model that capitalizes on a blend of front-end presence, partnerships, and a distributor model. With this approach, the company leverages its broad and diverse product line to target various market dynamics effectively.
Emcure’s pipeline of innovative pharmaceuticals and unique biologics portfolio support the company’s innovative business model. The organization hopes to maintain its growth trajectory in the Rest of the World (RoW) market by prioritizing increased market penetration and putting a well-measured plan into action.
Emcure Pharmaceuticals – Revenue Model
Emcure Pharmaceuticals’ revenue channels emphasize a strategic balance between emerging, domestic, and international markets, ensuring a diversified and resilient profile with a robust international footprint. For FY2023, below is the revenue generated from various markets:
- 46% of revenue came from the domestic market
- 16% from emerging markets
- 30% from regulated markets of Canada and Europe and the rest from other segments including contract manufacturing for Avet.
Emcure Pharmaceuticals – Challenges Faced
As the pharmaceutical industry continued to grow and more distinct product options were available, Emcure Pharmaceuticals faced several obstacles. Emcure faced a major difficulty as a result of increased rivalry from other pharmaceutical firms due to the rising prevalence of drug usage.
The changing nature of worldwide pharmaceuticals and the rules that accompany them presented the company with constant hurdles, especially since a significant amount of its revenue came from sales in other countries. For Emcure, traversing global markets faced challenges due to changing regulations and a changing landscape.
Furthermore, Emcure faced difficulties as a result of COVID-19, especially with its efforts to create COVID-19 vaccinations. The pandemic’s effects created complications that have an impact on these vaccines’ clinical trials.
Emcure Pharmaceuticals – Funding and Investors
Emcure Pharmaceuticals raised around $50 million (INR 310.60 crore) in 2006 from Blackstone. This infusion of capital not only fortified Emcure’s standing in the pharmaceutical sector but also empowered the company to expand its operations and propel its research and development initiatives to new heights.
Emcure Pharmaceuticals – Growth
Emcure Pharmaceuticals, one of the leading pharmaceutical firms in India, is a leader in the development, production, and international marketing of a wide range of pharmaceutical products covering several essential therapeutic areas.
Emcure’s noteworthy position in terms of domestic sales highlights both its steady expansion and its major influence in the pharmaceutical industry. Emcure Pharmaceuticals is a leading pharmaceutical company that drives growth by innovation, quality, and a wide product range. It has made a significant contribution to the improvement of healthcare in India and around the world.
Some of the growth highlights of Emcure Pharmaceuticals are:
- It has a presence in 70+ countries as of July 2024.
- It has 350+ brands in India as of July 2024.
- The company has 5 R&D centers as of July 2024.
- It has 13 manufacturing facilities as of July 2024.
- According to the Moving Annual Total (MAT) figures for February 2024, the company is the 11th largest pharmaceutical company in India.
- The company has 22 subsidiaries as of July 2024.
- The company has an R&D team of over 500 scientists as of July 2024.
Financials
| Emcure Pharmaceuticals Financials | FY23 |
|---|---|
| Operating Revenue | Rs 5,986 crore |
| EBITDA | 19.7% |
| Net Profit | Rs 561.8 crore |
Emcure Pharmaceuticals – IPO
Emcure Pharmaceuticals shares made a strong debut on July 10, 2024, listing at INR 1,325.05, a 31.5% premium over the issue price of INR 1,008. This impressive debut followed a successful Initial Public Offering (IPO) that attracted significant investor interest. Emcure’s IPO, which took place from July 3 to July 5, was a book-built issue valued at INR 1,952.03 crores. The IPO is managed by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited, with Link Intime India Private Ltd acting as the registrar.
Emotional morning today… we got listed at NSE 🙂 68 times oversubscribed, listed at 31% price premium but my Mirza Ghalib shayari sums up my feelings… congratulations Team Emcure ! pic.twitter.com/wQhmfmOjyq
— Namita (@namitathapar) July 10, 2024
Emcure Pharmaceuticals – Marketing and Campaigns
Emcure Pharmaceuticals has launched its new corporate campaign, “Cure and Beyond,” featuring cricketer MS Dhoni. The campaign highlights innovation as key to Emcure’s operations and aims to establish thought leadership in the Indian pharmaceutical market. The ad is being showcased across digital, television, and print media.
MS Dhoni and Emcure make a formidable team for Cure and Beyond
Emcure Pharmaceuticals – Awards and Achievements
Emcure Pharmaceuticals, with an extensive portfolio of brands, has earned multiple awards, affirming its excellence and leadership in the pharmaceutical industry.
2018
- Instgra – Best New Introduction of the Year Silver Award by AWACS (21-50-Chronic & Sub Chronic Category).
- Orofer XT – Brand of the Year award for Marketing Excellence – Gold Award by AWACS.
- Emluz – Best New Introduction of the Year Gold Award by AWACS.
- Best Indian Patents Award 2017-18 (Highest Number of granted patents) by Indian Drug Manufacturers Association.
- National Safety Council – Maharashtra Safety Award – 2018 for Zero Accident.
2019
- Brand of the Year award for Marketing Excellence -Bronze Award by AWACS Orofer-XT.
- Best API Patents Award 2018-19 (Highest Number of API patents) by the Indian Drug Manufacturers Association.
- Process Development and Commercialization Award 2019 for the development of Tenectase, a 3rd generation thrombolytic glycoprotein for acute ischemic stroke (AIS).
- DISH-Narayan Meghaji Lokhande Health & Safety Award 2019 – Industrial Best Practices.
2020
- Pronto Consult Consumer Award – Platinum Impact Award Vylda.
2021
- Exafib – CIMS Medica Healthcare Excellence Award 2021 – Emerging Brand of the Year (Cardiac Care).
- CIMS Medica Healthcare Excellence Award 2021 – Most Engaging Scientific Platform from Pharma Company.
- Pronto Consult Consumer Award –Golden Impact Award Ferium 500 Inj.
2022
- Awarded the Silver Impact Award at Pronto Consult Award for Vylda
- Awarded the 1st runner up at the AWACS Pharmarack Awards for New Introduction of the Year above 2,000 crores – Chronic for Dydrofem
Emcure Pharmaceuticals – Competitors
As mentioned due to the wide options in the pharmaceutical companies, Emcure Pharmaceuticals has tough competitors.
Emcure Pharmaceutical competes with the following companies:
- Sun Pharma
- Abbott India
- Dr. Reddy’s Laboratories
- Biocon Limited
- Cipla
- Torrent Pharmaceuticals
- Alkem Laboratories
- Intas Pharmaceuticals
- Natco Pharma
- Amneal Pharmaceuticals
- Supriya Lifescience
Emcure Pharmaceuticals – Future Plans
The company is well-positioned to take advantage of favorable conditions for its public market debut after the launch of its IPO. The company’s resubmission is consistent with its forward-thinking strategy and shows its dedication to flexibility and wise decision-making when pursuing strategic expansion prospects.
Shalini Rath
FAQs
Who is the founder of Emcure Pharmaceuticals?
Satish Ramanlal Mehta is the founder, CEO, and Managing Director of Emcure Pharmaceuticals.
What is the operating revenue of Emcure Pharmaceuticals?
The operating revenue of Emcure Pharmaceuticals was Rs 5,986 crore in FY23.
What is the valuation of Emcure Pharmaceuticals?
The leading pharma company, Emcure Pharmaceuticals has a valuation of $50 billion as of September 2023.
